Clinical trials: DDI (Drug-Drug Interaction)
Type 2 Diabetes Mellitus
A Study to Evaluate the DDI of HSK7653 With Metformin
This is a Phase 1, single center, open-label, single arm, drug-drug interaction study of HSK7653 and metformin in Healthy Subjects.
- Trial name
- NCT06084156
- Testing
- HSK7653, Metformin
- Where
- China
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Diabetes Mellitus Type 2
CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)
The purpose of this study is to evaluate a pharmacokinetic drug interaction between sitagliptin and lobeglitazone in healthy male volunteers.
- Trial name
- NCT02827890
- Testing
- Januvia Tab. 100mg, Januvia Tab. 100mg + Duvie Tab. 0.5mg
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy
Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
This study will evaluate the potential drug interactions between ALXN2050 and cyclosporine (Part 1), between ALXN2050 and tacrolimus (Part 2), and between ALXN2050 and mycophenolate mofetil (MMF) (Part 3).
- Trial name
- NCT05202145
- Testing
- ALXN2050, Cyclosporine, Tacrolimus
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Drug Drug Interaction (DDI)
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
- Trial name
- NCT07265466
- Testing
- JP-1366 and clopidogrel, JP-1366 and aspirin, JP-1366 and atorvastatin
- Where
- South Korea
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Onconic Therapeutics Inc.
HIV Infections
DDI HV (ATV - Merck)
The purpose of this study is to to assess the effect of ATV 300 mg BID on the PK of raltegravir 400 mg BID, to assess the effect of raltegravir 400 mg BID on the PK of ATV 300 mg BID, and to assess the ECG effects of ATV 300 mg…
- Trial name
- NCT00518297
- Testing
- Raltegravir, Atazanavir, Atazanavir + Raltegravir
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Drug Interaction Potentiation
Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg
Healthy male volunteers were administered alone and in combination with dapoxetine 30mg mirodenafil 50mg for three times, respectively and the pharmacokinetic interaction was compared between the two drugs.
- Trial name
- NCT02485028
- Testing
- Dapoxetine 30mg tablet, Mirodenafil 50mg tablet
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Healthy Volunteers
Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study
This study will assess the effect of dexpramipexole on the pharmacokinetics (PK) of the CYP2C9 probe substrate warfarin in healthy volunteers.
- Trial name
- NCT01597310
- Testing
- Warfarin, Dexpramipexole
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences
Drug Drug Interaction
Drug-Drug Interaction (DDI) Study in Healthy Volunteers
A Phase 1, Open Label, Fixed Sequence Study to Evaluate the Effect of BLD-0409 on the Single Dose Pharmacokinetics of a Cocktail of Probe Substrates for CYP450 Enzymes in Healthy Volunteers
- Trial name
- NCT04814498
- Testing
- Geneva Cocktail, BLD-0409
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Blade Therapeutics
Healthy
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants
The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on how fast different formulations of midazolam gets into the blood stream and how long it takes the body to remove it when administered in…
- Trial name
- NCT06180967
- Testing
- Midazolam Syrup, Midazolam Solution, Pirtobrutinib
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Eosinophilic Esophagitis
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.
- Trial name
- NCT05175352
- Testing
- Cendakimab, CYP substrates
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- Celgene
Dermatitis Atopic
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
This is an open-label, single group, 2-period, Phase 1, single-sequence study. The study duration will be up to 342 days. The treatment period will be up to Week 29, where Week 29 is defined as End of Treatment (last amlitelimab…
- Trial name
- NCT06686628
- Testing
- Amlitelimab, Midazolam, Caffeine
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Sanofi
Healthy
A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants
The primary purpose of this study is to assess the effect of nipocalimab on the pharmacokinetic (PK) of etanercept (Part 1); and to assess the effect of hydroxychloroquine (HCQ) on total serum immunoglobin G (IgG) reduction by…
- Trial name
- NCT04973566
- Testing
- Nipocalimab, Etanercept, Hydroxychloroquine
- Where
- Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Adult Subjects
A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
This study will assess the potential for clinical drug-drug interactions between omaveloxolone and a number of substrates and inhibitors of metabolic enzymes and drug transporters.
- Trial name
- NCT04008186
- Testing
- Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Biogen
Drug Interaction Potentiation
Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg
Healthy male volunteers were administered alone and in combination with dapoxetine 30mg mirodenafil 100mg for three times, respectively and the pharmacokinetic interaction was compared between the two drugs.
- Trial name
- NCT02485041
- Testing
- Dapoxetine 30mg, Mirodenafil 100mg
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Healthy Adult Subject, Overweight Subject
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
The purpose of this study is to characterize the effect of HDM1002 on the PK of single dose of repaglinide, atorvastatin, digoxin and rosuvastatin in healthy adult subjects.
- Trial name
- NCT06601517
- Testing
- Repaglinide, Atorvastatin, Digoxin
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Psoriasis
Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects
This is a phase 1, multi-center, open-label, drug-drug interaction (DDI) and PK study in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT01937260
- Testing
- Brodalumab
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 31 people
- Sponsor
- Bausch Health Americas, Inc.
Multiple Sclerosis
GSK239512 DDI Study
The study will determine the effect of 400 mg once daily of ketoconazole at steady state on the pharmacokinetics of a single oral dose of GSK239512 in young healthy volunteers.
- Trial name
- NCT01802931
- Testing
- GSK239512, ketoconazole
- Where
- Australia
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infection, Human Immunodeficiency Virus
A Open-label, Drug-Drug Interaction With Maraviroc (DDI)
This is a Phase 1, open-label, single sequence, two-way interaction study in healthy male and female subjects. For the effect of maraviroc on the pharmacokinetics (PK) of BMS-626529 (the active moiety of BMS-663068), there is no…
- Trial name
- NCT02480894
- Testing
- BMS-663068, Maraviroc
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)
This is an open-label, single sequence, 4-cycle, 4-treatment, drug-drug interaction (DDI) study in healthy female subjects on oral contraceptives (OC). There is no formal research hypothesis to be statistically tested.
- Trial name
- NCT02480881
- Testing
- BMS-663068, Oral Contraceptive, Loestrin 1.5/30
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy
Drug-drug Interaction (DDI) With a P-gp Inhibitor, Organic Anion Transporting Polypeptide OATP-inhibitor, Food Effect
The primary objective of this trial is to investigate the relative bioavailability of BI 685509 given alone under fasted conditions (Reference, R) compared to the intake after a high fat, high caloric breakfast (Test 1, T1), to…
- Trial name
- NCT03116893
- Testing
- BI 685509 After Standardised Breakfast, Itraconazole, Rifampin
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim